SCHEMBL16147348

SCHEMBL16147348

COc1cc2c(cc1OC)CN(Cc1ccccc1-n1cnc3ccccc31)C(C)C2

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA2 P00918 1/20 0.43
CA9 Q16790 1/20 0.43
KDM4E B2RXH2 1/20 0.40
MAPT P10636 1/20 0.40
TDP1 Q9NUW8 1/20 0.40
GPR55 Q9Y2T6 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
FGFR1 P11362 2/20 0.38
HTT P42858 3/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
PLK1 P53350 2/20 0.38
PTGER2 P43116 1/20 0.37
HPGD P15428 3/20 0.37
ALDH1A1 P00352 1/20 0.37
LMNA P02545 1/20 0.37
NEK2 P51955 1/20 0.37
SRC P12931 1/20 0.37
NPSR1 Q6W5P4 1/20 0.36
ADRA2B P18089 1/20 0.36
PDE10A Q9Y233 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16147483 0.94 KDM4E (0.43) CA2CA9KDM4EMAPTTDP1
SCHEMBL16148687 0.92 CA2 (0.38) CA2CA9KDM4EMAPTTDP1
SCHEMBL16148303 0.90 HPGD (0.42) CA2CA9KDM4EMAPTTDP1
SCHEMBL16147261 0.90 FGFR1 (0.44) CA2CA9KDM4EMAPTTDP1
SCHEMBL16147924 0.89 FGFR1 (0.44) CA2CA9KDM4EMAPTTDP1
SCHEMBL16148311 0.88 CA2 (0.35) CA2CA9KDM4EMAPTTDP1
SCHEMBL16148825 0.88 KDM4E (0.37) KDM4EMAPTTDP1GPR55L3MBTL1
SCHEMBL17498811 0.87 HTT (0.45) HTTSMN1; SMN2HPGDALDH1A1LMNA
SCHEMBL17498777 0.84 SLC6A5 (0.42) KDM4EFGFR1HTTSMN1; SMN2HPGD
SCHEMBL16147392 0.83 FGFR1 (0.48) MAPTFGFR1HTTSMN1; SMN2HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10617685-B2 Nonsteroidal and steroidal compounds with potent androgen receptor down-regulation and anti prostate cancer activity UNIVERSITY OF MARYLAND, BALTIMORE (US) 2020-04-14 US disclosed
EP-3514147-A1 STEROIDAL COMPOUNDS WITH POTENT ANDROGEN RECEPTOR DOWN-REGULATION AND ANTI PROSTATE CANCER ACTIVITY University of Maryland, Baltimore (US) 2019-07-24 EP disclosed
US-20170266181-A1 NONSTEROIDAL AND STEROIDAL COMPOUNDS WITH POTENT ANDROGEN RECEPTOR DOWN-REGULATION AND ANTI PROSTATE CANCER ACTIVITY UNIVERSITY OF MARYLAND, BALTIMORE (US) 2017-09-21 US disclosed
EP-2991644-A2 NONSTEROIDAL AND STEROIDAL COMPOUNDS WITH POTENT ANDROGEN RECEPTOR DOWN-REGULATION AND ANTI PROSTATE CANCER ACTIVITY University of Maryland, Baltimore (US) 2016-03-09 EP disclosed
WO-2014165815-A2 NONSTEROIDAL AND STEROIDAL COMPOUNDS WITH POTENT ANDROGEN RECEPTOR DOWN-REGULATION AND ANTI PROSTATE CANCER ACTIVITY UNIVERSITY OF MARYLAND, BALTIMORE (US) 2014-10-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10617685-B2 Nonsteroidal and steroidal compounds with potent androgen receptor down-regulation and anti prostate cancer activity AR, NR5A1, BRCA1 CA2 4418/4885CA9 4158/4885KDM4E 1575/4885
US-20170266181-A1 NONSTEROIDAL AND STEROIDAL COMPOUNDS WITH POTENT ANDROGEN RECEPTOR DOWN-REGULATION AND ANTI PROSTATE CANCER ACTIVITY AR, NR5A1, BRCA1 CA2 4418/4885CA9 4158/4885KDM4E 1575/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.